Clinical trials are being conducted by Concert Pharmaceuticals Inc., to investigate a new treatment called CTP‑543 in adults, age 18 to 65 years, with at least 50% hair loss. This research study will look at 2 different dosing regimens (schedules) of CTP-543 when given to research participants with alopecia areata for a total of 24 weeks. Participants must have a diagnosis of alopecia areata and have an ongoing episode of current hair loss lasting between 6 months and not exceeding 10 years. Participants should not be taking any medicine to treat hair loss or that alter the immune system. Additional study entry requirements will be confirmed at the participating trial sites.
If eligible to participate in the study, total time in the study will last up to 32 weeks (11 visits to the trial site), and up to 24 weeks on study treatment. Following the study treatment period in this study, you may be eligible to join another study and continue taking CTP‑543. Study visits will occur every 2 weeks for the first two months then monthly thereafter. Changes in hair loss will be checked every 4 weeks and blood will be taken for safety monitoring and research.
Go to www.clinicaltrials.gov and search for CTP-543 for a full description of the study and a listing of all trial site locations. Additional information can be obtained by contacting canaaf@gmail.com.
